Eisai Co (4523) AI Stock Analysis

• Market Cap: ¥1.39T
• Dividend Yield: 3.51%
• Average Volume (3M): 1.34M
• Price to Earnings (P/E): 19.1
• Beta (1Y): 0.98
• Revenue Growth: 6.79%
• EPS Growth: 22.14%
• Country: JP
• Employees: 11,067
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 291,649,140
• 10 Day Avg. Volume: 1,231,250
• 30 Day Avg. Volume: 1,336,443
• PEG Ratio: 2.35
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 1.49
• P/FCF Ratio: 64.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,559.62
• Price Target Upside: 12.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: ¥4,974.00 ▲(0.57% Upside)
• Action: Downgraded Date: 02/10/26
• Date: Action: Downgraded 02/10/26

The score is driven primarily by strong financial performance (sharp TTM revenue rebound, resilient margins, and conservative leverage), partially tempered by cash-flow volatility and only mid-level returns on equity. Technicals are mixed with negative MACD and price below key medium-term averages, while valuation is balanced by a solid dividend yield but a relatively high P/E.

Positive Factors

Strong revenue rebound

A 47.2% TTM revenue rebound indicates durable product traction and demand across Eisai's core therapeutic areas. Sustained top-line growth improves funding capacity for R&D and lifecycle expansion, bolstering long-term commercial momentum and strategic optionality.

Negative Factors

Cash-flow volatility

Historic swings in operating and free cash flow reduce predictability of internal funding for trials and commercialization. FCF/NetIncome ~0.75 shows conversion below parity, increasing reliance on timing decisions for working capital or external funding in weaker periods.

Eisai Co Business Overview & Revenue Model

Company Description

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunc...

Read more

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunc...

How the Company Makes Money

Eisai generates revenue primarily through the sale of its pharmaceutical products, which are distributed globally across various markets. The company derives significant income from its flagship products, particularly in oncology and neurology. Ad...

Read more

Eisai generates revenue primarily through the sale of its pharmaceutical products, which are distributed globally across various markets. The company derives significant income from its flagship products, particularly in oncology and neurology. Ad...

Eisai Co Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	808.19B	789.40B	741.75B	744.40B	756.23B	645.94B
Gross Profit	628.38B	597.23B	563.77B	543.48B	569.79B	465.19B
EBITDA	89.22B	103.73B	86.15B	79.20B	98.02B	92.84B
Net Income	42.76B	46.43B	42.41B	55.43B	47.95B	42.12B
Balance Sheet
Total Assets	1.49T	1.39T	1.39T	1.26T	1.24T	1.09T
Cash, Cash Equivalents and Short-Term Investments	319.40B	265.56B	304.68B	267.35B	309.63B	248.74B
Total Debt	231.04B	231.18B	206.75B	170.92B	143.03B	131.27B
Total Liabilities	570.56B	520.58B	494.82B	440.78B	467.78B	362.07B
Stockholders Equity	889.64B	841.42B	875.61B	799.96B	748.82B	703.18B
Cash Flow
Free Cash Flow	72.94B	18.18B	41.67B	-24.35B	88.56B	54.70B
Operating Cash Flow	86.55B	30.12B	55.99B	-1.77B	117.59B	73.85B
Investing Cash Flow	-25.51B	-10.10B	-25.32B	-22.72B	-28.85B	-36.87B
Financing Cash Flow	-45.54B	-57.81B	-22.72B	-24.52B	-48.97B	-55.91B

Eisai Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4946.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4523, the sentiment is Positive. The current price of 4946 is above the 20-day moving average (MA) of 4916.38, above the 50-day MA of 4821.95, and above the 200-day MA of 4543.35, indicating a bullish trend. The MACD of 77.56 indicates Negative momentum. The RSI at 50.85 is Neutral, neither overbought nor oversold. The STOCH value of 48.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4523.

Eisai Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4507	84 Outperform	¥2.97T	8.09	12.22%	2.22%	4.48%	11.08%
4521	80 Outperform	¥151.10B	93.62	-2.58%	4.16%	-5.99%	-96.04%
4516	77 Outperform	¥343.57B	9.44	―	2.12%	4.07%	22.59%
4502	70 Neutral	¥8.93T	18.42	0.54%	4.11%	-2.84%	-88.29%
4523	68 Neutral	¥1.39T	19.13	5.75%	3.51%	6.79%	22.14%
4506	56 Neutral	¥783.06B	26.11	48.92%	―	29.92%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%